12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
12 Week Open Label, Multicenter, Non-Comparative Switch Study Evaluating Efficacy, Tolerability And Safety Of Oral Ziprasidone In Treatment Of Patients Suffering From Schizophrenia Who Have Already Been Treated With An Other Antipsychotic.
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Terminated
See Detailed Description for Termination Reason
Other terminated trials from Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Pulmonary Arterial Hypertension · Phase PHASE4 · Feb 2021
- Bipolar Disorder · Phase PHASE3 · Jul 2020
- Bipolar Disorder · Phase PHASE3 · May 2020
- Chronic Low Back Pain With a Neuropathic Component · Phase PHASE4 · Jun 2015
- Adenomatous Polyposis Coli · Phase PHASE3 · Oct 2013
More terminations from Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Other Schizophrenia trials with similar outcome
A PHASE4 clinical study on Schizophrenia, this trial is terminated or withdrawn. The trial is conducted by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. and has accumulated 7 data snapshots since 2003. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Mar 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Mar 2021 [monthly]
Terminated PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE4
First recorded
Nov 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
For direct contact, visit the study record on ClinicalTrials.gov .